Archive

Skip to content The CRC Digest Organ preservation after neoadjuvant immunotherapy in dMMR/MSI-H CRC A review examines response-adapted organ preservation in mismatch repair-deficient colorectal cancer following neoadjuvant immune checkpoint blockade, noting that evidence for surgery avoidance remains immature and anatomically uneven between colon and rectal cancer. (Front Oncol) This

Skip to content The CRC Digest Fulminant pelvic metastasis in 44-year-old with KRAS/TP53 co-mutations A case report describes a 44-year-old female with microsatellite-stable sigmoid colon cancer who developed a massive pelvic seeding metastasis driven by concurrent KRAS and TP53 mutations; an abdominopelvic CT 8 months earlier had been unremarkable.

Skip to content The CRC Digest ▪ SCREENING Quantitative FIT levels predict colorectal cancer risk across clinical settings In a retrospective cohort of 3,663 colonoscopy patients, FIT levels were significantly higher in the 567 CRC cases (2,113.90 vs 615.99 ng/ml; p < 0.001), supporting risk

Skip to content The CRC Digest ▪ SCREENING Two-step screening strategy shows long-term effectiveness in China A cohort of 295,706 participants underwent fecal immunochemical testing or questionnaire-based risk assessment, with positive results triggering colonoscopy referral; the study estimated absolute risk reductions and numbers needed to screen for CRC incidence and

Skip to content The CRC Digest ▸ TREATMENT Omitting 5-FU bolus in mCRC: survival and toxicity outcomes A retrospective multicentre cohort of 267 metastatic CRC patients compared bolus-free nbFOLFOX (n=141) with standard mFOLFOX6 (n=126), with or without bevacizumab or anti-EGFR therapy, to assess impact on progression-free survival and overall

Skip to content The CRC Digest ◇ RESEARCH Mutant KRAS drives aberrant RNA modification in colorectal cancer In isogenic cell and animal models, mutant KRAS—present in 40-50% of CRC patients—upregulates m6A mRNA modification by stabilizing the METTL3 protein and inhibiting its degradation via p62-driven selective autophagy. (Adv Sci) This

Skip to content The CRC Digest ◇ RESEARCH Multicellular networks drive immunotherapy resistance in MSS colorectal cancer A review synthesizes evidence that microsatellite-stable CRC—comprising 85-90% of cases—remains refractory to PD-1/PD-L1 monotherapy (objective response rate 5-10%) because tumor-associated macrophages, cancer-associated fibroblasts, regulatory T cells, and myeloid-derived suppressor cells cooperate